An Innovative Canadian Pharmaceutical Company

Revenue Projected at $160,000,000 by 2025

Valeo Pharma Inc. Profile

300 x 100



Why Valeo Pharma?

  • Q2-21 record revenues of $2.65 million
    • up 27% vs Q2-20
    • up 42% over prior quarter
  • Q3-21 revenues expected to increase by more than 50% over Q2-21
  • 2020 net revenues of $7.5 million
    • up 14% vs 2019
  • Commercial stage revenue generating Canadian pharmaceutical company
  • Approaching EBITDA positive in coming months
  • 9 products currently marketed ($40M. estimated peak sales / year)
  • 7 additional products in pipeline ($45M. estimated peak sales / year)
  • In-license business model, no development or clinical risk
  • Hesperco™ Capsules at the Core of Montreal Heart Institute's Hesperidin Coronavirus Clinical Trial

What Exactly Does Valeo Pharma Do?

  • Acquires Canadian rights to commercial stage, innovative and proprietary drugs
  • Commercializes innovative prescription products in Canada
  • Focused on Neurodegenerative Diseases,  Oncology and Hospital Specialty Products
  • Internally manages portfolio through all stages of commercialization

Commercial Portfolio

Here’s just a few products already approved:


Launch: Q1-2021

Status: Approved by Health Canada December 2020

Indication: Injectable blood thinner

Market size:  $200M

Received positive recommendation for public reimbursement in Quebec

To be covered under Ontario Public Drug Benefit program

Peak sales estimate $30 - $40M, sales margin 55 - 60%


Launch: Launched in Q4 -2020

Status: Approved by Health Canada

What is it: Anti-Oxidant - Immune system support

How’s it sold: Retail, Online (,

Market Size: $500M




Launch: Q3 2019

Status: Received positive recommendation for public reimbursement in Quebec

Use: Parkinson's disease, 1st treatment launched in Canada since 2006

Patient base: 100,000 in Canada 2nd chronic neurodegenerative disorder after Alzheimer

Market Size: $20M

%Peak sales estimate $8M, sales margin 65-70 % Onstryv


The Valeo ModelThe-Model

Company Forecast

  • All portfolio & pipeline products to be on the market by end 2022
  • Solid pipeline composed of “licensed” products
  • Peak Sales reached 2-4 years after market launch
  • From 1 product on the market to 12 in 4 years and more to come
  • Forecast excludes any new product licensing
Last changed at 09-Jul-2021 01:15PM by AGORACOM